肺がん患者における塩酸アムルビシン化学療法による副作用の解析 : 化学療法ワークシート作成の試み

概要

論文の詳細を見る
To investigate the safety profile of amrubicin hydrochloride (AMR), we conducted a review of adverse drug reactions (ADRs) due to AMR in records of patients treated at Toyama University Hospital. Using the results, we designed a new AMR chemotherapy worksheet for lung cancer. The design of the new worksheet was based on that of existing reports. In 13 inpatients treated with a total of 30 courses of AMR chemotherapy during the period of the review, though the AMR dose was lower than the recommended dose, neutropenia and thrombopenia of grade 4 in the Common Terminology Criteria for Adverse Events v 3.0 (CTCAE) occurred in half of them. While non-hematological toxicities of grade 4 were not observed, some patients had persistent nausea, anorexia, and general malaise. Antiemetic 5-HT_3 antagonists were administered to most of the patients, and 3 courses of concomitantly administered dexamethasone achieved perfect remission of nausea and vomiting. In the new worksheet, AMR dose-limiting toxicities, history of taking anthracyclines, and previous hematological toxicities are recorded for checking prescriptions. It also includes a table of possible ADRs, their symptoms and time of occurrence for monitoring purposes, as well as a notice to patients to pay attention to nonproductive cough and dyspnea, the initial symptoms of interstitial pneumonia.
日本医療薬学会の論文
2008-02-10